# Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

> **NCT07701889** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 21 (estimated)

## Conditions studied

- Hematologic Diseases

## Interventions

- **BIOLOGICAL:** 20-19 Tan BB06oz CAR T

## Key facts

- **NCT ID:** NCT07701889
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2028-10
- **Final completion:** 2029-10
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701889, "Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07701889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*